A PRISMA-compliant meta-analysis on association between X-ray repair cross complementing (XRCC1, XRCC2, and XRCC3) polymorphisms and oral cancer susceptibility.

Abstract

Oral Cancer (OC) is one of the leading causes of death and the disease mainly occurs over 50years of age. Herein, a meta-analysis aimed to assess the association between X-ray repair cross complementing (XRCC) polymorphisms and OC risk. Four databases were searched extensively until June 5, 2020. Subgroup analysis, meta-regression, and funnel plots, as well as the quality assessment were estimated. Fifteen studies were entered to the analysis. With regards to allele, homozygote, heterozygote, recessive, and dominant models, the pooled ORs for XRCC1 rs1799782 polymorphism were 1.51 (P=0.01), 1.45 (P=0.11), 1.45 (P=0.0003), 1.44 (P=0.0002), and 1.29 (P=0.26); for XRCC1 rs1799782 polymorphism were 1.65 (P=0.11), 1.50 (P=0.33), 1.06 (P=0.83), 1.57 (P=0.12), and 1.32 (P=0.45); for XRCC1 rs25489 polymorphism were 0.01 (P=0.19), 1.44 (P=0.48), 1.21 (P=0.72), 1.17 (P=0.19), and 1.38 (P=0.54); for XRCC2 rs2040639 polymorphism were 0.68 (P=0.0002), 0.63 (P=0.02), 0.95 (P=0.92), 0.79 (P=0.49), and 0.61 (P=0.005); and for XRCC3 rs861539 polymorphism were 1.24 (P=0.20), 1.28 (P=0.48), 0.99 (P=0.95), 1.15 (P=0.46), and 1.52 (P=0.15), respectively. The T allele and CT genotype of XRCC1 rs1799782 polymorphism had an elevated risk, whereas the G allele and GG genotype of XRCC2 rs2040639 polymorphism had a protective role in OC.